VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.
To view the full press release, visit https://ibn.fm/ka00j
At a glance
- Company
- VERAXA Biotech
- Ticker
- Nasdaq: VRXA
- Announcement
- Acquisition
Key figures
- Senior secured note
- $27.5 million
- Securities purchase agreement
- up to $50 million
Products and programs
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.
For regular updates about VERAXA Biotech, visit www.veraxa.com
About Voyager Acquisition Corp.
Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry.
For more information, please visit https://www.voyageracq.com
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What happened in VERAXA Biotech’s business combination with Voyager Acquisition Corp.?
The transaction closed and resulted in the formation of VERAXA Biotech AG. The company said its shares would begin trading on the Nasdaq Capital Market under VRXA, while its warrants would trade under VRXAW. The release describes the closing as the completion of a previously announced business combination.
How does a business combination involving a special purpose acquisition company work?
A special purpose acquisition company, or SPAC, is formed to pursue a merger or other transaction with an operating business. When a deal closes, the operating business may become publicly traded through the combination. The specific structure, approvals and financial terms vary by transaction, and the announcement describes the outcome of this particular deal rather than the general process.
What are bispecific T-cell engagers and antibody-drug conjugates?
Bispecific T-cell engagers are engineered antibodies designed to bind both a target on a cancer cell and a target on a T cell, bringing the immune cell close to the cancer cell. Antibody-drug conjugates link an antibody that recognizes a target to a drug payload, with the goal of delivering that payload to cells bearing the target.
What did VERAXA report about its lead candidate’s preclinical data?
The company said it presented preclinical data on its lead BiTAC-TCE candidate at the AACR Annual Meeting 2026. VERAXA characterized the data as demonstrating favorable efficacy and safety characteristics. The announcement does not provide detailed study results or describe clinical testing of the candidate.
SEC filings
- 6-KReport of a foreign issuer Filed
- 20-FAnnual report of a foreign issuer Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- SCHEDULE 13DSCHEDULE 13D Filed
- 6-KReport of a foreign issuer Filed
- CERTCERT Filed
- 8-A12B/A8-A12B/A Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
- 3PRIMARY DOCUMENT Filed
